Use Of Medical Scans In Patients Who Experience Pain Might Prompt Unnecessary Increase In Health Care Costs The New York Times on Tuesday, as part of an occasional series titled "The Evidence Gap," examined how medical scans, which have become "more sensitive and easily available than ever," are "increasingly finding abnormalities that may not be the cause of the problem for which they are blamed.
Source: www.medicalnewstoday.comAcelRx Pharmaceuticals Reports Positive Results From A Phase 2 Clinical Trial Of Sublingual Sufentanil NanoTabs(TM) In Treating Post-Operative Pain AcelRx Pharmaceuticals, Inc. announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery. The primary endpoint evaluated pain intensity (Sum of the Pain Intensity Difference - SPID12) over the 12-hour study period compared to baseline.
Source: www.medicalnewstoday.comEncore Therapeutics Inc. Demonstrates Proof Of Concept For A Long-Acting Buprenorphine Depot For Pain And Drug Abuse Therapy (ETI-311) Encore Therapeutics Inc. (ETI) today reported that ETI-311, the company's novel long-acting depot for buprenorphine, produced clinically relevant plasma levels of the drug over 3-7 days when administered by intradermal injection in dog studies. These results add to the growing number of applications for ETI's drug delivery platform technology to deliver
drugs both locally and systemically in a high-load and continuous manner.
Source: www.medicalnewstoday.com
# posted by Network @ 11:00 AM
